MT-125 is named as a drug or biological intervention in 2 clinical trials in our USA trial register, 1 of which is recruiting. The lead sponsor is Myosin Therapeutics Inc.. Registered phase: Phase 1/2. Conditions studied include Glioblastoma; Glioblastoma (GBM).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07185880 | A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients (ClinicalTrials.gov ↗) Glioblastoma (GBM) |
Phase 1/2 | Recruiting |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma (ClinicalTrials.gov ↗) Glioblastoma |
Phase 1/2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Glioblastoma | 1 |
| Glioblastoma (GBM) | 1 |
| Lead sponsor | Trials |
|---|---|
| Myosin Therapeutics Inc. | 2 |
| Register | MT-125 trials |
|---|---|
| Clinical trials in USA | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MT-125 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MT-125 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.